Connecting clients, partners and patients to develop new treatments for diabetes and related metabolic diseases.
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment Read More »
ProSciento Appoints Dr. Kelvin Logan, Former Executive at INC Research and Quintiles, to its Board of Directors Read More »
View Our Presentation
FDA Advisory Committee votes: Victoza provides substantial evidence of CV risk reduction in patients with T2DM Read More »
Results from the CANVAS trial for J&J’s SGLT-2 inhibitor Invokana published in NEJM Read More »
ProSciento partners with OWL Metabolomics to advance recruitment strategies for NASH clinical studies Read More »